Vaccines for melanoma: Translating basic immunology into new therapies

Lancet Oncology

Volumn 2, Issue 4, 2001, Pages 205-211

  Wolchok, J D ^a   Livingston, P O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; GANGLIOSIDE; HEAT SHOCK PROTEIN; SUBUNIT VACCINE;

DENDRITIC CELL; HUMAN; IMMUNOLOGY; MELANOMA; REVIEW; SKIN TUMOR;

CANCER VACCINES; DENDRITIC CELLS; GANGLIOSIDES; HEAT-SHOCK PROTEINS; HUMANS; MELANOMA; SKIN NEOPLASMS; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 0035322914     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00290-4     Document Type: Review

References (59)

1. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol. 14:1996;7-17.
2. Oettgen H.F., Old L.J. The history of cancer immunotherapy. DeVita V.T., Hellman S., Rosenberg S.A. Biologic therapy of cancer. First ed. 1991;87-120 JB Lippincott Company, Philadelphia.
3. Foley E. Antigenic properties of methylcholanthrene-induced tumours in mice of the strain of origin. Cancer Res. 13:1953;835-837.
4. Prehn R.T., Main J.M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 18:1957;769-778.
5. Hewitt H.B., Blake E.R., Walder A.S. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer. 33:1976;241.
6. Takahashi T., Johnson T.D., Nishinaka Y., et al. IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol. 112:1999;205-209.
7. Hsueh E.C., Gupta R.K., Qi K., Morton D.L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol. 16:1998;2913-2920.
8. Reynolds S.R., Celis E., Sette A., et al. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol. 161:1998;6970-6976.
9. Berd D., Murphy G., Maguire H.C., Mastrangelo M.J. Immunisation with haptenized, autologous tumour cells induces inflammation of human melanoma metastases. Cancer Res. 51:1991;2731-2734.
10. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumour cell engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumour immunity. Proc Natl Acad Sci USA. 90:1993;3539-3543.
11. Soiffer R., Lynch T., Mihm M., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumour immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA. 95:1998;13141-13146.
12. Ellem K.A., O'Rourke M.G., Johnson G.R., et al. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother. 44:1997;10-20.
13. Dranoff G., Soiffer R., Lynch T., et al. A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther. 8:1997;111-123.
14. Zhang S., Cordon-Cardo C., Zhang H.S., et al. Selection of tumour antigens as targets for immune attack using immunuhistochemistry: I. Focus on gangliosides. Int J Cancer. 73:1997;42-49.
15. Livingston P.O., Wong G.Y.C., Adluri S., et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomised trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 12:1994;1036-1044.
16. Helling F., Zhang S., Shang A., et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 55:1995;2783-2788.
17. Chapman P.B., Morrissey D.M., Panageas K.S., et al. Induction of antibodies against GM2 ganglioside by immunising melanoma patients using GM2-KLH + QS21 vaccine: a dose-response study. Clin Cancer Res. 6:2000;874-879.
18. Ragupathi G., Meyers M., Adluri S., et al. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer. 85:2000;659-666.
19. Cheung N.-K.V., Canete A., Cheung I.Y., et al. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. Int J Cancer. 54:1993;499-505.
20. Saleh M.N., Stapleton J.D., Khazaeli M.B., LoBuglio A.F. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J Immunol. 151:1993;3390-3398.
21. Sen G., Chakraborty M., Foon K.A., et al. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin Cancer Res. 3:1997;1969-1976.
22. Foon K.A., Lutzky J., Baral R.N., et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol. 18:2000;376-384.
23. Yao T.-J., Meyers M., Livingston P.O., et al. Immunisation of melanoma patients with BEC2-Keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunisations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res. 5:1999;77-81.
24. McCaffery M., Yao T.-J., Williams L., et al. Enhanced immunogenicity of BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside when combined with adjuvant. Clin Cancer Res. 2:1996;679-686.
25. Marchand M., van Baren N., Weynants P., et al. Tumour regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 80:1999;219-230.
26. Weber J.S., Hua F.L., Spears L., et al. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J Immunother. 22:1999;431-440.
27. Lee P.P., Yee C., Savage P.A., et al. Characterisation of circulating T cells specific for tumour-associated antigens in melanoma patients. Nat Med. 5:1999;677-685.
28. Salgaller M.L., Marincola F.M., Cormier J.N., Rosenberg S.A. Immunisation against epitopes in the human melanoma antigen gp100 following patient immunisation with synthetic peptide. Cancer Res. 56:1996;4749-4757.
29. Jager E., Bernhard H., Romero P., et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumour vaccines with melanoma-associated antigens. Int J Cancer. 66:1996;162-169.
30. Storkus WJ, Kirkwood JM, Mayordomo JI, et al. Melanoma peptide vaccine: a randomised phase I evaluation of MART-1, gp100, and tyrosinase peptide vaccines in patients with malignant melanoma. Proc Am Soc Clin Oncol 1996; 15: (abstr 1811).
31. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 4:1998;321-327.
32. Wang F., Bade E., Kuniyoshi C., et al. Phase I trial of a MART-1 peptide vaccine in incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res. 5:1999;2756-2765.
33. Jager E., Ringhoffer M., Dienes H.P., et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer. 67:1996;54-62.
34. Zarour H.M., Kirkwood J.M., Kierstead L.S., et al. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA. 97:2000;400-405.
35. Cormier J.N., Salgaller M.L., Prevette T., et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am. 3:1997;37-44.
36. Lee K.-H., Wang E., Nielsen M.B., et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumour regression. J Immunol. 163:1999;6292-6300.
37. Weeratna R.D., McCluskie M.J., Xu Y., Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine. 18:2000;1755-1762.
38. Kaplan G., Walsh G., Guido L.S., et al. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med. 175:1992;1717-1728.
39. Schaed SG, Houghton AN, Klimek VM, et al. Immunisation of melanoma patients with both tyrosinase (370D) and GP100 (210M) peptides: comparison of adjuvants and peptide immunogenicity. Proc Annu Meet Am Assoc Cancer Res 2000; 41: (abstr 4029).
40. Heike M., Noll B., Meyer zum Buschenfelde K.H. Heat shock protein-peptide complexes for use in vaccines. J Leukoc Biol. 60:1996;153-158.
41. Janetzki S., Blachere N.E., Srivastava P.K. Generation of tumour-specific cytotoxic T lymphocytes and memory T cells by immunisation with tumour-derived heat shock protein gp96. J Immunother. 21:1998;269-276.
42. Srivastava P.K., Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol. 6:1994;728-732.
43. Srivastava P.K. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods. 12:1997;165-171.
44. Blachere N.E., Srivastava P.K. Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumours. Semin Cancer Biol. 6:1995;349-355.
45. Castellino F., Boucher P.E., Eichelberg K., et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med. 191:2000;1957-1964.
46. Arnold-Schild D., Hanau D., Spehner D., et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol. 162:1999;3757-3760.
47. Porgador A., Irvine K.R., Iwasaki A., et al. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunisation. J Exp Med. 188:1998;1075-1082.
48. Casares S., Inaba K., Brumeanu T.D., et al. Antigen presentation by dendritic cells after immunisation with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J Exp Med. 186:1997;1481-1486.
49. Akbari O., Panjwani N., Garcia S., et al. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med. 189:1999;169-178.
50. Klinman D.M., Yi A.K., Beaucage S.L., et al. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA. 93:1996;2879-2883.
51. Sato Y., Roman M., Tighe H., et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunisation. Science. 273:1996;352-354.
52. Bowne W.B., Srinivasan R., Wolchok J.D., et al. Coupling and uncoupling of tumour immunity and autoimmunity. J Exp Med. 190:1999;1717-1722.
53. Hawkins W.G., Gold J.S., Dyall R., et al. Immunisation with DNA coding for gp100 results in CD4+ T-cell independent antitumour immunity. Surgery. 128:2000;273-280.
54. Weber L.W., Bowne W.B., Wolchok J.D., et al. Tumour immunity and autoimmunity induced by immunisation with homologous DNA. J Clin Invest. 102:1998;1258-1264.
55. Wang R., Doolan D.L., Le T.P., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282:1998;476-480.
56. Boyer J.D., Cohen A.D., Vogt S., et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis. 181:2000;476-483.
57. Ugen K.E., Nyland S.B., Boyer J.D., et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine. 16:1998;1818-1821.
58. Nestle F.O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat Med. 4:1998;328-332.
59. Thurner B., Haendle I., Roder C., et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 190:1999;1669-1678.